GlassScriptPhysician profile
Vivaik Tyagi
NPI 1073612545
$27,954.24
in general payments reported to CMS, 2019-2025
39 companies · $1,148 in 2025
The $1,148 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,341 · 2020: $548 · 2021: $1,170 · 2022: $1,343 · 2023: $14K · 2024: $7,930 · 2025: $1,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $5,079 · Travel and Lodging: $1,176 · Education: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,085.00 |
| Food and Beverage | $5,078.76 |
| Travel and Lodging | $1,175.87 |
| Education | $211.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $17,233.55 | 2020-2025 | Epclusa |
| Abbvie INC. | $2,861.06 | 2019-2025 | Skyrizi, Rinvoq, Mavyret |
| Nestle Healthcare Nutrition INC. | $2,159.64 | 2021-2023 | |
| Janssen Biotech, INC. | $945.92 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $779.90 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $593.84 | 2019-2025 | Entyvio, Gattex |
| Endogastric Solutions, INC | $347.11 | 2019-2022 | |
| Boston Scientific Corporation | $287.69 | 2022-2023 | Axios, Resolution Clip |
| Pfizer INC. | $274.29 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $267.23 | 2021-2022 | |
| Genzyme Corporation | $247.13 | 2022-2024 | |
| Ardelyx, INC. | $224.15 | 2023-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $219.19 | 2020-2023 | Linzess |
| Phathom Pharmaceuticals, INC. | $208.36 | 2024-2025 | Voquezna |
| Tempus Ai, INC | $165.84 | 2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $137.35 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $134.59 | 2019-2024 | Dificid |
| Regeneron Healthcare Solutions, INC. | $118.32 | 2022-2025 | Dupixent |
| Dova Pharmaceuticals | $96.94 | 2019 | |
| Evoke Pharma, INC. | $83.47 | 2021-2023 | Gimoti |
| Braintree Laboratories, INC. | $76.02 | 2020-2021 | |
| Redhill Biopharma INC. | $70.32 | 2020-2024 | Talicia |
| Shionogi INC | $69.05 | 2019 | |
| Madrigal Pharmaceuticals | $66.17 | 2025 | Rezdiffra |
| Echosens North America, INC. | $36.11 | 2019-2020 | |
| Capsovision, INC. | $33.99 | 2025 | Capsocam Plus |
| Ipsen Biopharmaceuticals, INC | $32.25 | 2025 | Iqirvo |
| Qol Medical, LLC | $30.57 | 2024 | Sucraid |
| Astrazeneca Pharmaceuticals LP | $29.25 | 2019 | |
| Daiichi Sankyo INC. | $22.04 | 2021 | |
| Shire North American Group INC | $20.90 | 2019 | |
| Pinnacle Biologics, INC | $20.80 | 2020 | |
| Intercept Pharmaceuticals, INC. | $17.49 | 2023 | Ocaliva |
| Micro-Tech Endoscopy USA, INC. | $14.77 | 2025 | Riteclip |
| Ferring Pharmaceuticals INC. | $14.65 | 2020 | |
| Alfasigma USA, INC. | $14.29 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivaik Tyagi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.